AstraZeneca GMG drug recommended for EU approval
25th Jul 2022 07:56
(Sharecast News) - AstraZeneca said its treatment for the rare autoimmune neuromuscular disease generalised myasthenia gravis (GMG) has been recommended for marketing authorisation in the European Union as an add-on to standard therapy for adult patients who are anti-acetylcholine receptor (AChR) antibody-positive.
Read moreAstraZeneca asthma drug gets EU marketing approval
25th Jul 2022 07:43
(Sharecast News) - AstraZeneca's asthma treatment Tezspire has been recommended for marketing authorisation in the European Union as an add-on therapy in patients 12 years and older, the company said.
Read moreAstraZeneca breast cancer drug granted priority review by US FDA
25th Jul 2022 07:12
(Sharecast News) - Drugmaker AstraZeneca said on Monday that its Enhertu metastatic breast cancer asset had been granted priority review status in the US following results from its DESTINY-Breast04 trial.
Read moreAstraZeneca breast cancer drug granted priority review by US FDA
25th Jul 2022 07:12
(Sharecast News) - Drugmaker AstraZeneca said on Monday that its Enhertu metastatic breast cancer asset had been granted priority review status in the US following results from its DESTINY-Breast04 trial.
Read moreAstraZeneca's HER2-positive breast cancer drug receives EU approval
19th Jul 2022 07:02
(Sharecast News) - Drugmaker AstraZeneca's Enhertu has received European Union approval to be used as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer.
Read moreAstraZeneca agrees to acquire TeneoTwo
5th Jul 2022 07:04
(Sharecast News) - Drugmaker AstraZeneca has agreed to acquire TeneoTwo and its clinical-stage T-cell engager in a deal worth up to $1.26bn as part of an effort to accelerate the development of the potential new medicine for B-cell haematologic malignancies.
Read moreCovid-19 cases surge during latest week due to BA.4 and BA.5 Covid-19 sub-variants
1st Jul 2022 13:22
(Sharecast News) - The number of new coronavirus cases in Britain jumped again during the preceding week, likely due to the more infectious BA.4 and BA.5 variants of the Omicron variant of Covid-19.
Read moreOxford Biomedica signs new Covid vaccine deal with AstraZeneca
1st Jul 2022 07:03
(Sharecast News) - Oxford Biomedica has signed a new three-year deal to make AstraZeneca's Covid-19 vaccine beyond this year when the original agreement expires, the company said on Friday.
Read moreAstraZeneca receives positive interim results from lung cancer drug trial
30th Jun 2022 07:13
(Sharecast News) - Pharmaceutical giant AstraZeneca has received positive results from a planned interim analysis of the AEGEAN Phase III trial on its resectable non-small cell lung cancer drug.
Read moreAstraZeneca's breast cancer drug recommended for EU marketing authorisation
27th Jun 2022 07:04
(Sharecast News) - Drugmaker AstraZeneca said on Monday that Lynparza, its HER2-negative high-risk early breast cancer drug, has been recommended for marketing authorisation in the European Union after demonstrating "a statistically significant and clinically meaningful" improvement in invasive disease-free survival.
Read moreCiti reiterates 'buy' on AstraZeneca on the back of trial results for Enhertu against breast cancer
22nd Jun 2022 10:06
(Sharecast News) - Analysts at Citi reiterated their 'buy' recommendation for shares of AstraZeneca following the release of the results of the DESTINY-Breast 04 clinical trial using its Enhertu treatment against metastatic breast cancer.
Read moreAstraZeneca receives 'positive' results from Phase III trial on eplontersen
21st Jun 2022 08:13
(Sharecast News) - Drugmaker AstraZeneca has received positive high-level results from an interim analysis of its NEURO-TTRansform Phase III trial on eplontersen, the group's hereditary transthyretin-mediated amyloid polyneuropathy drug candidate.
Read moreBerenberg stays at 'buy' for AstraZeneca after trial results for Enhertu against breast cancer
6th Jun 2022 17:48
(Sharecast News) - Analysts at Berenberg reiterated their 'buy' recommendation with a 120.0p target price for shares of AstraZeneca following the release of the company's clinical trial results for its treatment against metastatic breast cancer.
Read moreAstraZeneca-Daiichi's Enhertu reports positive survival rate results
6th Jun 2022 07:47
(Sharecast News) - A treatment for breast cancer developed by AstraZeneca and Daiichi Sankyo has been shown to double the progression-free survival rates of patients compared with chemotherapy, according to trial data released on the weekend at a conference.
Read moreAstraZeneca autoimmune treatment meets trial endpoint
5th May 2022 08:42
(Sharecast News) - AstraZeneca said its treatment for an autoimmune disease that attacks the central nervous system had met a primary endpoint in a phase 3 trial.
Read more